long-acting β2-agonists (LABA)

PreclinicalSmall molecule

long-acting β2-agonists (LABA) is one of 36 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

AsthmaActive, not recruiting

Chronic Obstructive Pulmonary DiseasePreclinical

Active, not recruiting

AsthmaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

17 2

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 3

Spiriva

Boehringer Ingelheim

Preclinical

8 4

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 5

Aclidinium Bromide

AstraZeneca

Preclinical

—6

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 7

Allergen Immunotherapy Extract

JJohns Hopkins University

Preclinical

1 8

Inhaled Corticosteroids

Boehringer Ingelheim

Preclinical

6 9

Guanidine Hydrochloride

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

FP/SAL

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05393245·19,467 enrolled

Asthma1 trial

Exacerbation Risk in Asthma

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05501639·1,899 enrolled

Corticosteroids1 trial

Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05402020·17,018 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for long-acting β2-agonists (LABA). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — long-acting β2-agonists (LABA) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for long-acting β2-agonists (LABA). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

long-acting β2-agonists (LABA)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Asthma1 trial

Corticosteroids1 trial

References

Drug Info

Quick Facts

Related News